Triple drug cocktail takes on pancreatic cancer
NCT ID NCT01204372
First seen Mar 16, 2026 · Last updated Jun 19, 2026 · Updated 15 times
Summary
This phase 2 trial tested a combination of three drugs—gemcitabine, trastuzumab, and erlotinib—as a first treatment for people with metastatic pancreatic cancer. 63 patients received the drugs intravenously and orally. The goal was to see how well the combo controlled the disease and how safe it was.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre Val d'Aurelle
Montpellier, 34298, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
gemcitabine, trastuzumab, and erlotinib
What this could lead to
If this combination works well, it could offer a new first-line treatment option for people with metastatic pancreatic cancer, potentially slowing the disease.
What could go wrong
This is a small, early-phase trial with no comparison group, so results are uncertain. The drugs can cause serious side effects, and the cancer may still progress.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.